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http://www.cardiothoracicsurgery.org/content/19/1/167RESEARCH ARTICLE Open AccessEarly administration of levosimendan is associated
with improved kidney function after cardiac
surgery – a retrospective analysis
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Klaus-Dieter Wernecke3 and Jan P Braun1,4Abstract
Background: Several animal studies suggest beneficial effects on kidney function upon administration of levosimendan.
As recent data from clinical studies are heterogeneous, we sought to investigate whether levosimendan is associated
with improved postoperative kidney function in cardiac surgery patients with respect to timing of its administration.
Methods: Retrospective, single centre, observational analysis at a university hospital in Berlin, Germany. All adult
patients without preoperative renal dysfunction that underwent coronary artery bypass grafting and/or valve
reconstruction/replacement between 01/01/2007 and 31/12/2011 were considered for analyses.
Results: Out of 1.095 included patients, 46 patients were treated with levosimendan due to a severely reduced
left ventricular systolic function preoperatively (LVEF < 35%) and/or clinical signs of a low cardiac output syndrome.
Sixty-one percent received the drug whilst in the OR, 39% after postoperative intensive care unit admission. When
levosimendan was given immediately after anaesthesia induction, creatinine plasma levels (p = 0.009 for nonparametric
analysis of longitudinal data in a two-factorial design) and incidence of postoperative renal dysfunction (67.9% vs. 94.4%;
p = 0.033) were significantly reduced in contrast to a later start of treatment. In addition, duration of renal replacement
therapy was significantly shorter (79 [35;332] vs. 272 [132;703] minutes; p = 0.046) in that group.
Conclusions: Postoperative kidney dysfunction is a common condition in patients under going cardiac surgery. Patients
with severely reduced left ventricular function and/or clinical signs of a low cardiac output syndrome who preoperatively
presented with a normal kidney function may benefit from an early start of levosimendan administration, i.e. immediately
after anaesthesia.
Trial registration: Clinicaltrials.gov-ID: NCT01918618.
Keywords: Levosimendan, Kidney function, Renal effects, Cardiac surgery, Left ventricular ejection fractionBackground
Cardiac surgery is associated with a high risk for peri- and
postoperative complications [1]. In consequence, protect-
ing organ function in the operative setting plays an im-
portant role for improving patient outcome. Postoperative
renal dysfunction is associated with increased mortality
of 60-90%, and especially in patients undergoing cardiac* Correspondence: felix.balzer@charite.de
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unless otherwise stated.surgery, prolonged stays on the intensive care unit (ICU)
and in the hospital have been reported [2].
Levosimendan is a long acting calcium sensitizer derived
from pyridazinone-dinitrile [3]. It enhances contractil-
ity without increasing oxygen consumption by calcium
concentration-dependent conformational changes in
troponine C. Coronary as well as systemic vasodilatation
are mediated by opening potassium channels on vascular
smooth muscle. Levosimendan is also able to reduce car-
diac stunning without increasing myocardial intracellular
calcium concentrations or prolonging myocardial relax-
ation [4,5]. Anti-apoptotic properties in combination with
a protective effect against ischemic injury in the hearttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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have been described [6,7]. However, current European
guidelines recommend levosimendan only as ultima ratio
therapy in patients suffering decompensated heart failure
in a non-operative setting [8,9]. Levosimendan has only re-
cently been approved for perioperative usage in Germany
and in consequence, its usage varies among cardiac anaes-
thesiologist and intensive care practitioners.
Although several animal studies suggest beneficial effects
on kidney function upon administration of levosimendan
[10,11], recent data from the surgical setting are hetero-
geneous [12-14]. For instance, Bragadottir et al. reports
increased cardiac output, promoted renal vasodilatation,
increased renal blood flow and glomerular filtration rate
(GFR) with an unchanged renal oxygen supply–demand
relationship in patients receiving levosimendan [15]. In
patients on a left ventricular assist device (LVAD) levo-
simendan application was associated with a reduced time
spent on renal replacement therapy (RRT) [16]. On the
contrary, levosimendan administration did not result in
significant differences for creatinine, cystatin C and urine
N-acetyl-b-glucosaminidase (NAG) postoperatively in pa-
tients with left ventricular ejection fraction (LVEF) below
50% undergoing coronary artery bypass grafting surgery
[17]. In this context, levosimendan may be capable of pro-
tecting organ function as long as no further tissue damage
has been caused during surgery. Given these suggested
beneficial effects, we conducted a retrospective, obser-
vational analysis to evaluate postoperative kidney function
in cardiac surgery patients with respect to timing of levosi-
mendan administration.
Methods
After approval of the respective ethics board (Chairperson
Prof. Dr. R. Uebelhack, Study ID number: EA1-044-13;
ClinGov. registration number: NCT01918618), we reviewed
the charts and data derived from two electronic patient
data management systems (COPRA System, Sasbachwalden,
Germany and SAP, Walldorf, Germany) of all patients
(≥18 years) admitted to our 28-beds ICU of the depart-
ment of anaesthesiology and intensive care medicine at
the Campus Charité Mitte, Berlin, between 01/01/2007
and 31/12/2011. Inclusion criteria were: a) cardiac surgery
with CPB, b) no pre-existing renal dysfunction defined as
creatinine plasma level > 2.0 mg/dl (SI 176.8 μmol/L) [18],
and c) administration of levosimendan on the day of
surgery. Levosimendan administration was triggered by
a severely reduced left ventricular systolic function pre-
operatively (LVEF < 35%) and/or clinical signs of a low car-
diac output syndrome (LCOS) intraoperatively and/or in
the immediate postoperative course. Exclusion criteria
were: a) incomplete medical records, b) patient age below
18. In order to evaluate postoperative kidney function,
incidence of renal dysfunction defined as at least onepostoperative creatinine plasma level > 1.5 times the pre-
operative value (based on the creatinine criterion of the
KDIGO classification) and/or the need for renal replace-
ment therapy (RRT) [19], duration of renal replacement
therapy and differences in the time course of creatinine
plasma levels postoperatively until day four were chosen
as study endpoints.
Cardiopulmonary bypass (CPB) and anaesthesia manage-
ment was performed according to our standard operating
procedures [20,21]. Normothermic CPB was established
with a non-pulsatile flow of 2,5 l/min/m2 and an arterial
pressure > 60 mmHg without additional filtration. CPB
was primed with balanced electrolyte solution, hydroxyethyl
starch, 1000 mg methylprednisolone and 500 mg tranex-
amic acid. Coagulation was offset by 400 IE•kg heparin
aiming at an Activated Clotting Time (ACT) > 410 seconds.
Additionally, all patients received tranexamic acid. Cardio-
plegic arrest was induced and maintained by intermittent
administration of ante grade warm potassium enriched
blood [22].
Perioperative goal-oriented haemodynamic support was
established according to institutional standards guided by
the German S3 guidelines [8]. Intraoperatively, patients
with a preoperative reduced LVEF (<35%) and/or open
cardiac surgery, e.g. valve reconstruction and/or replace-
ment, were monitored with transoesophageal echocardiog-
raphy (TEE, Vivid 7 or Vivid S6, GE, Fairfield, USA) and/or
a pulmonary artery catheter with continuous mixed venous
oximetry measurement. In case of difficult CPB separ-
ation despite hemodynamic optimization, an intraaortic
balloon pump (IABP) was placed according to the team’s
assessment.
After chest closure, the patient was transferred intubated
and mechanically ventilated to the ICU. Patients were kept
sedated with propofol (1–3 mg/kg/h) and opioid bolus ad-
ministration until cardiopulmonary stability was achieved
(i.e. heart rate 80–100 beats/min, mean arterial pres-
sure 65–85 mmHg, central venous pressure 8–12 mmHg
(at positive end-expiratory pressure 5 cm H2O), pul-
monary artery occlusion pressure 12–15 mmHg, car-
diac index >2.5 l /min/m2, stroke volume index >30 ml/m2,
mixed venous oxygen saturation >65), chest tube drainage
was negligible (<100 ml/h), and the patient was judged to
be extubated. If mechanical ventilation was required ≥
12 hours, analgosedation was switched to midazolam 0.01 -
0.2 mg/kg/h combined with sufentanil 0.15 - 0.7 μg/kg/h,
and weaning from mechanical ventilation was performed
according to the standard operating procedures at our hos-
pital [21,23]. Hemodynamic optimization was continuously
accomplished according to the German S3 guidelines [8].
The decision for RRT was taken in consultation with the
department of nephrology and based on the following
criteria: a) oliguria < 500 ml/dl and/or anuria < 100 ml/dl,
b) metabolic acidosis, c) hyperkaliaemia, and d) uraemia.
Table 1 Morphometric and demographic data and
surgical procedures
Levo OR Levo ICU
P value
(n = 28) (n = 18)
Age (years) 66 ± 10 67 ± 11 0.535
Weight (kg) 82.1 ± 15.9 81.5 ± 15.0 0.928
Height (m) 1.76 ± 0.1 1.72 ± 0.1 0.167
Body mass index (kg/m2) 26.3 ± 3.9 27.9 ± 5.0 0.286
Sex (men/women) 22/6 13/5 0.622
Procedure
CABG 15 5 0.114
VR 5 8 0.051
CABG + VR 8 5 0.953
NYHA III/IV 25 16 0.966
Coronary artery disease 23 13 0.426
LVEF (%) 31 ± 12 36 ± 15 0.233
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median ± quartiles or percentage, respectively. Normal
distribution was checked by the Kolmogorov-Smirnov
test. Differences between groups were analyzed by the
Mann–Whitney U-test. Non-directional hypothesis were
tested two-sided, whereas directional hypothesis were
tested one-sided. By categorical scaling, the relative fre-
quency of a variable was analyzed by the χ2-test. Changes
in variables over time were analyzed using a nonparamet-
ric analysis of longitudinal data in a two-factorial design.
Logistic regression analysis was performed to detect peri-
operative factors influencing renal function postopera-
tively. P < 0.05 was considered statistically significant.
All tests should be understood as constituting explora-
tory data analysis, such that no adjustments for mul-
tiple testing have been made. Statistics were performed
using SPSS 20.0 software (IBM Corporation, Armonk,
New York, USA).COPD 9 5 0.754
Peripheral vascular disease 7 5 0.834
Atrial fabrillation 17 9 0.474
Hyperlipidaemia 8 8 0.270




Arterial hypertension 13 9 0.813
Diabetes mellitus 16 12 0.518
Data are expressed as mean ± SD, numbers or percentage. CABG, coronary
arterial bypass grafting; VR, valve reconstrution and/or replacement; NYHA,
New York Heart Association; LVEF, left ventricular ejection fraction; COPD,
chronic obstructive pulmonary disease.
Table 2 Perioperative renal function parameters and
SAPS-II scores
Levo OR Levo ICU
P value
(n = 28) (n = 18)
Preoperative creatinineplasma (mg/dl) 1.19 ± 0.37 1.13 ± 0.26 0.753
Preoperative eGFR (ml/min) 73 ± 23 73 ± 21 0.928
Preoperative diuretic treatment (%) 21.4 38.9 0.343









Postoperative renal dysfunction is defined as a creatinine plasma level > 2.0 mg/dl.
Data are expressed as mean ± SD, median and quartiles or percentage. *indicate
significant differences between groups. Levo OR/Levo ICU, see text for further
details; OR, operating room; ICU, intensive care unit; eGFR, estimated glomerular
filtration rate; RRT, renal replacement therapy.Results
In total, 9.634 patients were admitted to our ICU during
the specified study period. Thereof 4.635 underwent elect-
ive or urgent cardiac surgery, namely coronary artery
bypass grafting (CABG) and/or valve reconstruction/
replacement (VR). After exclusion of patients with cre-
atinine plasma levels > 2.0 mg/dl, 1.095 patients were
considered for further analyses. In this cohort, 46 pa-
tients received 12.5 mg levosimendan once as a con-
tinuous infusion in a rate of 0.1 μg/kg/min on the day
of surgery without an initial bolus. 61% of the patients
received levosimendan intraoperative immediately after
anaesthesia induction (LEVO OR) and 39% postoperative
on ICU (LEVO ICU). Thereof, the mean time interval be-
tween ICU admission and start of levosimendan adminis-
tration was 1.4 hours (range 0 – 9 h).
Basic patient characteristics and surgical data are pre-
sented in Table 1. There were no significant differences
in functional status, i.e. NYHA classification or other co-
morbidities between groups. The preoperative creatinine
plasma level, the preoperative estimated GFR, number of
patients under preoperative diruretic therapy, and SAPS-
II admission score on ICU did not differ between groups
(Table 2). Despite normal creatinine plasma values, pre-
operative estimated GFR was mildly reduced in both
groups without statistical difference.
Incidence of postoperative renal dysfunction was signifi-
cantly reduced in patients who received levosimendan
after anaesthesia induction in contrast to those who
were given levosimendan first after admission on ICU
(67.9% vs. 94.4%, p = 0.033) (Table 2). In addition, early
onset of treatment was accompanied by a significant re-
duction in creatinine plasma levels (p = 0.009) in patients
not requiring RRT postoperatively (LEVO OR: n = 11;
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(p = 0.046) (Table 2).
Finally, the multivariate analysis showed that early ad-
ministration of levosimendan (i.e. in the operating room)
had significant independent influence on postoperative kid-
ney function (OR 0.043, 95% CI 0.002 – 0.940, p = 0.046).
Also the following perioperative conditions had a sig-
nificant influence on postoperative kidney function: a)
peripheral vascular disease (OR 0.044, 95% CI 0.001 –
0.906, p = 0.044), b) diabetes mellitus (OR 0.013, 95% CI
0.001 – 0.257, p = 0.004).Discussion
This retrospective analysis suggests an association of an
early – preventive – rather than a late start of levosimen-
dan administration and postoperative kidney function in
cardiac surgery patients. Levosimendan administration
seemed to be triggered in order to prevent or to imme-
diately begin treatment of LCOS in high-risk cardiac
surgery patients as these patients have the highest peri-
operative mortality [24]. However, when a patient received
levosimendan in the first course of postoperative treat-
ment (i.e. after being admitted to the ICU), it might have
been rather due to deteriorating physical conditions than
preventive aspects (i.e. after anaesthesia induction). This
in part might explain some of our findings. Nevertheless,
patients judged to require levosimendan received the drug
as “on top”-medication to the standard haemodynamic- - - - Levosimendan OR  (n = 11)
Levosimendan ICU (n = 5)
p
Figure 1 Time course of creatinine plasma levels in patients receiving
Postoperative creatinine plasma levels were significantly reduced when levosi
means ± SD. Preop = preoperative; Surgery = ICU admission; POD 1 – 4 = first to
after anesthesia induction in the operating room; LEVO ICU = start of levosimendoptimisation when other pharmacotherapeutical options
especially on ICU (i.e. epinephrine, etc.) were exhausted.
Considering the patients of our study that received
levosimendan intraoperatively, the results from our study
demonstrate a positive effect on renal function. This is
consistent with previous findings in patients with decom-
pensated heart failure [25-27] and also inline with a re-
cently published meta analysis in the perioperative setting
[28]. The aspect of timing of levosimendan administration
has been addressed by Aksun et al. [29] in a study involv-
ing 15 patients in total. They compared three groups
consisting of patients that were given levosimendan at
induction of anaesthesia, during weaning from CPB or
postoperatively. Whereas cardiac index (CI) and pulmon-
ary capillary wedge pressure (PCWP) improved and urine
output over 24 hours was satisfactory in all groups, pa-
tients of the group that received levosimendan whilst in
the ICU presented a prolonged necessity for inotropic
substances and also intraaortic balloon pumps. In patients
on LVAD perioperative levosimendan application was
associated with a shortend RRT duration [16].
In order to detect organ protective mechanisms of
levosimendan, only patients without preoperative elevated
creatinine plasma levels – as a simple and frequent access-
ible surrogate parameter of kidney function – were in-
cluded in this study. The 2.0 mg/dl limit is based on
current recommendations [18]. Considering the popula-
tion of this study, it would correspond to an estimated GFR
of 25–35 ml/min/1.73 m2 and correspond to “moderately = 0.009 
levosimendan intraoperatively or on ICU and not requiring RRT.
mendan was administered in the OR (p = 0.009). Values are expressed as
fourth postoperative day; LEVO OR= start of levosimendan administration
an administration after admission on ICU.
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KDIGO 2012 guidelines for staging of chronic kidney
disease [30]. Interestingly, this chosen limit ruled out
about ¾ of our cohort (4.635 to 1.095), indicating that
most patients with a preoperatively reduced LV function
were already affected by kidney dysfunction. Nevertheless,
pre-existing renal impairment in our study cohort may
have been masked by the already equally reduced pre-
operative estimated GFR in both groups. As too much
irreversible organ damage might have already been mani-
fested preoperatively, the organ protective properties of
levosimendan administration in heart failure patients might
be limited [31,32].
As early as 1984, Wilson et al. demonstrated impaired
skeletal muscle nutritive flow during exercise in patients
with congestive heart failure although stroke volume was
optimized by dobutamine infusion [33]. Consequently, im-
proving haemodynamics is one among several aspects in
the therapeutic course. Levosimendan, however, may also
positively influence cell surviving beside its properties to
restore haemodynamics [6,7].
Most aforementioned studies investigated non-operative
patients with decompensated heart failure. It might be
possible that additional beneficial effects of levosimendan
are attenuated by a systemic inflammation response syn-
drome (SIRS) concomitant with cardiac surgery [34,35]. In
experimental and clinical sepsis investigations, beneficial
renal effects of levosimendan were only detectable if the
drug improved haemodynamics [36-38].
This study stands out for its pragmatic clinical approach
in a real life environment. As for all retrospective ap-
proaches, our analysis was limited by the variables available
in routine patient care. The number of patients analyzed in
this study may be regarded as relatively high given the
single centre setting and the chosen eligibility criteria.
Since preoperative plasma creatinine, preoperative eGFR
and overall disease severity as expressed by SAPS-II admis-
sion score were statistically comparable between groups,
we found it reasonable to suggest that there was no statis-
tical bias with respect to the investigated parameters. In
our analysis, we can only assume that haemodynamics
were optimised as specified in the recent S3 guideline
[8]. In a previous study conducted in a similar setting,
there were no differences in use of norepinephrine, do-
butamine and enoximone between patients receiving
levosimendan or placebo [23]. Beneficial effects of nor-
epinephrine on kidney function have been described and
would thus add to the properties of levosimendan [39].
Nevertheless, additional factors like pharmalogical or
mechanical support may have had a significant impact
on outcome and suchlike issues need to be addressed
in controlled trials. Further preoperative risk stratifica-
tion using biomarkers might be another aspect of high
interest for future prospective studies [40].Up to date, the clinician’s decision to administer levosi-
mendan is mostly based on the clinical picture. Patients
that received levosimendan at a later point of time may
have been misjudged at first. Thus, a bias may never be
completely ruled out. The fact that levosimendan is used
off-label in most countries when administered in the peri-
operative setting also contributes to that bias. In this
context it is interesting that a large double-blind, placebo-
controlled, randomized, multicenter phase 3 trial is being
scheduled to start in the third quarter of 2014 in North
America to further investigate organ protective proper-
ties of levosimendan [41]. A multicentered phase 4 RCT
trial is currently undertaken at a university hospital in
Italy [42].
Conclusions
Patients with a normal or only slightly impaired kidney
function preoperatively may benefit from an early start
of levosimendan administration, i.e. immediately after
anaesthesia induction. Levosimendan administration in
patients after admission to the ICU, mainly due to a devel-
oping or already manifest LCOS, does not seem to be
beneficial to preserve kidney function. Considering the
pharmacokinetics of the long acting agent, further trials
are needed to evaluate assumed organ protective effects
of levosimendan when given even earlier (i.e. infused one
or two days preoperatively.
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